ライフサイエンスコーパス: INSTI

1 INSTI alone was not significantly associated with excess

2 INSTI DRMs were detected in 86 (14%) individuals; 20 (3%

3 INSTI resistance prevalence among successfully genotyped

4 INSTI use nearly doubled from pre- to peri-HCV treatment

5 INSTI use was associated with increased risk of new-onse

6 INSTI-CRR was 2.33% (0.15% dolutegravir/bictegravir, 2.2

7 INSTIs were prescribed to 22% of White patients and only

8 INSTIs work by blocking retroviral integration; an essen

9 nd rilpivirine coverage, compared with 14.0% INSTI PDR and 6.9% INSTI TDR with continued oral doluteg

10 , 549 non-INSTI) were included, and 280 (146 INSTI, 134 non-INSTI) had TE.

11 09 non-INSTI, 818 PWOH) compared to men (223 INSTI, 412 non-INSTI, 891 PWOH) were younger (47.2 vs 54

12 iduals, 47% started NNRTI-, 30% PI-, and 23% INSTI-based cART with median follow-up of 3.0, 2.3, and

13 iduals, 47% started NNRTI-, 30% PI-, and 23% INSTI-based cART with median follow-up of 3.0, 2.3, and

14 tance levels, with 30.6% INSTI PDR and 11.3% INSTI TDR at 30% LAI cabotegravir and rilpivirine covera

15 ong pharmacokinetic tail, resulting in 22.3% INSTI PDR and 26.0% rilpivirine PDR when using LAI cabot

16 A total of 872 WWH (323 INSTI, 549 non-INSTI) were included, and 280 (146 INSTI,

17 (INSTI-susceptible [INSTI-S] virus) and 35% (INSTI-R virus).

18 Of 3464 participants included, women (411 INSTI, 709 non-INSTI, 818 PWOH) compared to men (223 INS

19 Wild-type viruses were susceptible to the 5 INSTIs, with IC50s in the nanomolar range.

20 10 antiretroviral-experienced patients, to 5 INSTIs (bictegravir, cabotegravir, dolutegravir, elviteg

21 o higher INSTI resistance levels, with 30.6% INSTI PDR and 11.3% INSTI TDR at 30% LAI cabotegravir an

22 s from 236 IN inhibitor (INSTI)-naive and 60 INSTI-treated persons.

23 rage, compared with 14.0% INSTI PDR and 6.9% INSTI TDR with continued oral dolutegravir-based ART.

24 genotype; 12-week suppression rates are 90% (INSTI-susceptible [INSTI-S] virus) and 35% (INSTI-R viru

25 Continued average weight gain across INSTIs raises concerns about long-term cardiometabolic s

26 evaluated the effect of switching or adding INSTIs among WLHIV.

27 visualize the mode of action of the advanced INSTIs dolutegravir and bictegravir at near-atomic resol

28 characterization of metabolic changes after INSTI initiation and potential therapeutic interventions

29 red 6-12 months before and 6-18 months after INSTI switch/add in SWAD with comparable time points in

30 ng ART in earlier time periods but not after INSTIs became guideline-recommended initial therapy for

31 lls/mm3 after switch through 2 years for all INSTIs.

32 Prevalence was stable, although INSTIs were increasingly used.

33 ) from 2006-2017 who switched to or added an INSTI to ART (SWAD group) were compared to women on non-

34 ) from 2006-2017 who switched to or added an INSTI to ART (SWAD) were compared to women on non-INSTI

35 hydro-1,8-naphthyridine-3-carboxamides as an INSTI scaffold, making a limited set of derivatives, and

36 se follow-up of those patients initiating an INSTI-based regimen.

37 altegravir) at the virological failure of an INSTI-based regimen.

38 ssociated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m2/year; 95% confidenc

39 afenamide (IRR 1.70, 95% CI 1.54-1.88) or an INSTI without tenofovir alafenamide (1.41, 1.30-1.53) co

40 attenuated risk in participants receiving an INSTI with (IRR 1.48, 1.31-1.68) or without (1.25, 1.13-

41 was more common in individuals receiving an INSTI with tenofovir alafenamide (IRR 1.70, 95% CI 1.54-

42 f 29 340 participants had been exposed to an INSTI.

43 us should be considered when switching to an INSTI.

44 ants receiving tenofovir alafenamide with an INSTI (adjusted IRR 1.21, 1.07-1.37), whereas the risk i

45 s and 19 PHIV treated or not treated with an INSTI.

46 % confidence interval {CI}: -.29 to .32] and INSTI-: 0.22 cm per 6 months [95% CI: -.01 to .44]) that

47 e observed in 3.8%, NNRTI and PI in 0.6% and INSTI 1.1% of cases.

48 Furthermore, previously activated and INSTI-treated CD8 T cells demonstrated reduced capacity

49 .4% (34.6-42.1) on tenofovir alafenamide and INSTI-based regimens had gained more than 10% of their b

50 ties of Determine, Uni-Gold, SD Bioline, and INSTI were 99.8%.

51 I cabotegravir and rilpivirine coverage, and INSTI mutation reversion rates.

52 re was associated with diagnostic delays and INSTI resistance.

53 the reduced risk of HAND found with dual and INSTI-based regimens along with a more recent ART initia

54 d UGT1A1 genotypes that affect efavirenz and INSTI metabolism, respectively.

55 vement in survival between the pre-INSTI and INSTI recipients with HIV (adjusted hazard ratio [aHR],

56 ontrast to other mutations such as M184V and INSTI RAMs, NNRTI RAMs tended to persist within the HIV-

57 and IN mutations are important for NNRTI and INSTI resistance and viral fitness.

58 ore potential interactions between NNRTI and INSTI resistance mutations, we investigated the combined

59 e depiction of interactions of intasomes and INSTIs to be leveraged for structure-based drug design.

60 ions, 3' processing and strand transfer, and INSTIs tightly bind the divalent metal ions and viral DN

61 ple with viraemia on dolutegravir-based ART, INSTI DRMs and dolutegravir resistance were rare.

62 that show promising inhibitory potential as INSTI candidates.

63 studies have suggested associations between INSTIs and weight gain, women living with HIV (WLHIV) ar

64 studies have suggested associations between INSTIs and weight gain, women living with HIV (WLHIV) ha

65 om WWOH; there was also little difference by INSTI status.

66 magnitudes of these changes were observed by INSTI type.

67 magnitude of these changes were observed by INSTI type.

68 inhibition of the 3'-processing reaction by INSTIs and how INSTIs can be modified to overcome drug r

69 tutions in integrase that result in clinical INSTI failure perturb optimal magnesium ion coordination

70 Current INSTI use was associated with increased DM risk (IRR, 1.

71 of bictegravir, a novel, potent, once-daily INSTI designed to improve on existing INSTI options with

72 rate envelope concept that broadly effective INSTIs can be designed by filling the envelope defined b

73 atives, and concluded that broadly effective INSTIs can be developed using this scaffold.

74 to .23; P = .01), but not those on an entry INSTI >2 years.

75 d channelling bias cannot fully be excluded, INSTIs initiation was associated with an early onset, ex

76 -daily INSTI designed to improve on existing INSTI options with the backbone of emtricitabine and ten

77 V care from October 12, 2007, when the first INSTI was approved by the US Food and Drug Administratio

78 creased only within the first year following INSTI initiation among WWH.

79 Pretreatment assessment for INSTI resistance should not be recommended in treatment

80 Our findings suggest promise for INSTI-based strategies in this setting but underscore th

81 y, adjusted mean cognitive domain scores for INSTI-exposed infants were close to the expected populat

82 they limit the window of time available for INSTIs to block viral DNA integration.

83 Accordingly, SCAT and VAT samples from INSTI-exposed patients displayed higher levels of fibros

84 genic marker expression in SCAT and VAT from INSTI-treated noninfected macaques.

85 ecently approved the first second generation INSTI, GSK's Dolutegravir (DTG) (August 2013).

86 a third had been exposed to first-generation INSTIs (n=193, 32%), 70 (12%) were on dolutegravir dual

87 ed amidst expanding use of second-generation INSTIs and PrEP.

88 Although second-generation INSTIs present higher barriers to the development of vir

89 New "2nd-generation" INSTIs are needed that will have greater efficacy agains

90 sistant HIV-1 variants isolated from heavily INSTI-experienced patients proved to be susceptible to G

91 T initiation was estimated to lead to higher INSTI resistance levels, with 30.6% INSTI PDR and 11.3%

92 Highly INSTI-resistant HIV-1 variants isolated from heavily INS

93 d serve as salvage therapy agents for highly INSTI-resistant variant-harboring individuals.

94 For people treated for HIV, INSTI-based ART appears to be associated with a higher C

95 the 3'-processing reaction by INSTIs and how INSTIs can be modified to overcome drug resistance, nota

96 ed high-resolution structural studies of how INSTIs bind to their native drug target.

97 However, INSTI-exposed infants had slightly lower mean scores tha

98 d light on the fat modifications observed in INSTI-treated PHIV.

99 Neural tube defects were observed only in INSTI groups, with litter prevalence rates of 0.66% for

100 almost achieved, HIVDR mutations, including INSTIs resistance mutations were detected in HIV-positiv

101 Individual INSTI-based regimens among treatment-experienced AYAPHIV

102 egrase (IN) sequences from 236 IN inhibitor (INSTI)-naive and 60 INSTI-treated persons.

103 hat of the second generation INST inhibitor (INSTI) dolutegravir.

104 With integrase strand inhibitor (INSTI)-based regimens now recommended as first-line anti

105 rary of integrase strand transfer inhibitor (INSTI) candidates built around several chemical scaffold

106 to the integrase strand transfer inhibitor (INSTI) class; 1 patient discontinued DTG/ABC/3TC due to

107 des the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG).

108 Integrase strand transfer inhibitor (INSTI) resistance-associated mutations (RAMs) were detec

109 ays and integrase strand-transfer inhibitor (INSTI) resistance.

110 LA), an integrase strand transfer inhibitor (INSTI), reduces dosing frequency to bimonthly injections

111 eration integrase strand transfer inhibitor (INSTI), was recently approved for use in the treatment o

112 Integrase strand transfer inhibitor (INSTI)-based antiretroviral (ARV) therapies have been as

113 Integrase strand-transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is recommended

114 Integrase strand-transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is recommended

115 itiated integrase strand transfer inhibitor (INSTI)-based ART regimens, 1809 (31.7%) initiated protea

116 receive integrase strand-transfer inhibitor (INSTI)-based ART than among those who receive other ART

117 Integrase strand transfer inhibitor (INSTI)-based combination antiretroviral therapy (cART) i

118 Integrase strand transfer inhibitor (INSTI)-based combination antiretroviral therapy (cART) i

119 Integrase strand transfer inhibitor (INSTI)-based regimens became a first-line treatment for

120 started integrase strand transfer inhibitor (INSTI)-based regimens.

121 o newer integrase strand transfer inhibitor (INSTI)-based regimens.

122 ual and integrase strand transfer inhibitor (INSTI)-based therapies was associated with a decreased r

123 Integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART) is curren

124 smitted integrase strand transfer inhibitor (INSTI)-resistant (INSTI-R) virus is estimated at 0.1%.

125 ence of integrase strand transfer inhibitor (INSTI)-transmitted drug resistance (TDR) may increase wi

126 low-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those o

127 th non-integrase strand transfer inhibitor (-INSTI) or tenofovir alafenamide fumarate (TAF)-exposed p

128 Integrase strand transfer inhibitors (INSTI) and long-acting injectables offer potential for s

129 d integrase (IN) strand transfer inhibitors (INSTI) are key components of antiretroviral regimens.

130 RTANCE Integrase Strand Transfer Inhibitors (INSTI) are recommended by national and international gui

131 (HIV) integrase strand transfer inhibitors (INSTI) increases and formulations are being developed fo

132 cribed integrase strand transfer inhibitors (INSTI).

133 ns that include integrase strand inhibitors (INSTIs) have become the most commonly used for people wi

134 Integrase strand transfer inhibitors (INSTIs) and direct-acting antivirals (DAAs) have changed

135 Integrase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated w

136 Integrase strand transfer inhibitors (INSTIs) and the menopausal transition have been associat

137 1 integrase (IN) strand transfer inhibitors (INSTIs) approved by the FDA for the treatment of AIDS.

138 Integrase strand transfer inhibitors (INSTIs) are associated with weight gain in people with H

139 Integrase strand transfer inhibitors (INSTIs) are crucial for the treatment of human immunodef

140 Integrase strand transfer inhibitors (INSTIs) are highly effective against HIV infections.

141 Integrase strand transfer inhibitors (INSTIs) are now recommended components of frontline and

142 Integrase strand transfer inhibitors (INSTIs) are preferred for treatment of human immunodefic

143 on HIV integrase strand-transfer inhibitors (INSTIs) are prescribed throughout the world, the mechani

144 Integrase (IN) strand transfer inhibitors (INSTIs) are recent compounds in the antiretroviral arsen

145 Integrase strand transfer inhibitors (INSTIs) are recommended components of initial antiretrov

146 ommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy.

147 Integrase strand transfer inhibitors (INSTIs) coadministered with two nucleoside or nucleotide

148 aining integrase strand transfer inhibitors (INSTIs) combined with a tenofovir and lamivudine or emtr

149 n with integrase strand transfer inhibitors (INSTIs) has been associated with excess weight gain.

150 aining integrase strand transfer inhibitors (INSTIs) has been associated with weight gain in both ART

151 Integrase strand transfer inhibitors (INSTIs) have been associated with an increased risk for

152 h some integrase strand transfer inhibitors (INSTIs) promote peripheral and central adipose tissue/we

153 s were proven IN strand transfer inhibitors (INSTIs) that also displayed activity against ribonucleas

154 Integrase strand transfer inhibitors (INSTIs) were associated with more weight gain than prote

155 These IN strand-transfer inhibitors (INSTIs) were evaluated in vitro in cell-free enzyme acti

156 ion of integrase strand transfer inhibitors (INSTIs), but few studies have evaluated the safety of IN

157 ked by integrase strand transfer inhibitors (INSTIs), first-line antiretroviral therapeutics widely u

158 proved integrase strand transfer inhibitors (INSTIs), raltegravir (RAL) and elvitegravir (EVG).

159 which act as IN strand transfer inhibitors (INSTIs), were the first anti-IN drugs to be approved by

160 mechanism of IN strand transfer inhibitors (INSTIs), which are front-line drugs for the treatment of

161 drugs, integrase strand-transfer inhibitors (INSTIs).

162 n with integrase strand-transfer inhibitors (INSTIs).

163 nts including IN strand transfer inhibitors (INSTIs).

164 nts, 306 were exposed in utero to an initial INSTI-based maternal ART regimen, 473 to a PI-based regi

165 Among 1152 ART-naive PLWH, 351 initiated INSTI-based regimens (135 dolutegravir, 153 elvitegravir

166 Comprehensive Care Clinic cohort initiating INSTI-, protease inhibitor (PI)-, and nonnucleoside reve

167 cART-naive adults (>=18 years) initiating INSTI-, PI-, or NNRTI-based regimens from 01/2007-12/201

168 y-suppressed WWH (419 who switched to INSTI [INSTI+]; 712 who did not switch [INSTI-]) and 887 women

169 tter efficacy against a broad panel of known INSTI resistant mutants than any analogues we have previ

170 tion was diagnosed after exposure to CAB-LA, INSTI resistance and delays in the detection of HIV infe

171 vide mechanistic insights into why a leading INSTI retains efficacy against a broad spectrum of drug-

172 findings, virological benefits of first-line INSTIs-based ART might not translate to differences in m

173 Although VF rates with CAB/RPV were low, INSTI resistance emerged in approximately 40%-70% of ind

174 Major INSTI RAMs were detected in all 7 cases.

175 1 of 1316 drug-naive samples (0.1%), a major INSTI TDR mutation was detected.

176 erged in 4 cases and before additional major INSTI RAMs accumulated in 1 case.

177 NA testing identified infection before major INSTI RAMs emerged in 4 cases and before additional majo

178 In menopause, INSTI+ had faster increases, peaking at 43 months then d

179 ter linear increases in WC and in menopause, INSTI+ was associated with faster increases, peaking at

180 Most INSTI RAMs were detected early when the viral load was l

181 -1.53) compared with those receiving neither INSTIs nor tenofovir alafenamide.

182 fety data in pregnancy are limited for newer INSTIs.

183 Compared with those with no INSTI exposure, the risk of cardiovascular disease was i

184 ) were included, and 280 (146 INSTI, 134 non-INSTI) had TE.

185 18 PWOH) compared to men (223 INSTI, 412 non-INSTI, 891 PWOH) were younger (47.2 vs 54.5 years), were

186 A total of 872 WWH (323 INSTI, 549 non-INSTI) were included, and 280 (146 INSTI, 134 non-INSTI)

187 icipants included, women (411 INSTI, 709 non-INSTI, 818 PWOH) compared to men (223 INSTI, 412 non-INS

188 rget trial in those with previous use of non-INSTI-based ART (ie, ART-experienced) were the same exce

189 T (SWAD group) were compared to women on non-INSTI ART (STAY group).

190 to ART (SWAD) were compared to women on non-INSTI ART (STAY).

191 viduals had to have been on at least one non-INSTI-based ART regimen and be virally suppressed (<=50

192 rences, and fat percentages, compared to non-INSTI ART.

193 erences, and fat percentages compared to non-INSTI ART.

194 n-obese women, those in the INSTI versus non-INSTI group had a greater increase in NFS (but not FIB4

195 In RESPOND, compared with non-INSTIs, current use of INSTIs was associated with an inc

196 ial HIV-1 treatment with bictegravir-a novel INSTI with a high in-vitro barrier to resistance and low

197 No effect of INSTI resistance mutations on the fitness of RT-Y181C mu

198 eriod for diagnostic delays and emergence of INSTI resistance.

199 necessary to fully understand the impact of INSTI-based regimens on the health of the individual dur

200 Continued population-level monitoring of INSTI and NRTI mutations, especially M184V and K65R, is

201 ease was increased in the first 24 months of INSTI exposure and thereafter decreased to levels simila

202 Our results confirm the potency of INSTI on HIV-2 clinical isolates with wild-type integras

203 Delayed prescription of INSTI-containing ART may amplify differences and inequit

204 We analyzed the prevalence of INSTI TDR in the Swiss HIV Cohort Study (2008-2014).

205 e fumarate (TAF)-exposed persons, receipt of INSTI+TAF showed a 1.7-fold increased RR of excess gesta

206 d Uni-Gold were 100%, and the specificity of INSTI was 99.8%.

207 inically preferred unless DTG suppression of INSTI-R virus was <20% or 96-week DRV/r suppression was

208 Our results elucidate the binding of INSTIs to the HTLV-1 intasome and support their use for

209 Our findings suggest a direct effect of INSTIs and tenofovir alafenamide on bodyweight gain, rat

210 intasomes bound to the latest generation of INSTIs.

211 an and simian models to assess the impact of INSTIs on adipose tissue phenotype and function.

212 but few studies have evaluated the safety of INSTIs for infant neurodevelopment.

213 examining the role of the MBG in a series of INSTIs, we have identified a scaffold (hydroxypyrones) t

214 plex intasome, which is the direct target of INSTIs.

215 ddress some critical questions on the use of INSTIs in settings with a high tuberculosis burden, incl

216 ND, compared with non-INSTIs, current use of INSTIs was associated with an increased DM risk, which p

217 ding cannot be entirely excluded, the use of INSTIs was associated with incident hypertension, and th

218 TDR) may increase with the increasing use of INSTIs.

219 .5-24.9 kg/m(2), 31.3% (95% CI 29.5-33.1) on INSTI-based regimens, 25.3% (23.0-27.7) on protease inhi

220 studies have compared virological failure on INSTI-based with other regimens, few data are available

221 d adults with HIV-1 and >=10% weight gain on INSTI + tenofovir alafenamide (TAF)/emtricitabine (FTC;

222 Only INSTI-treated cells showed less migratory activity after

223 ive drug of a different class (NNRTI, PI, or INSTI) for at least 16 weeks.

224 hose third active agent was an NNRTI, PI, or INSTI, respectively.

225 Although oral INSTI regimens have a high barrier to emergent resistanc

226 ow-level resistance of HIV-1 to DTG or other INSTI were detected, and these were sometimes followed b

227 Bictegravir had a lower IC50 than the other INSTIs on those HIV-2 isolates bearing major, resistance

228 rticipants harboring resistance to the other INSTIs, raltegravir and elvitegravir.

229 Compared to INSTI-, in late perimenopause, INSTI+ had 0.26 cm per 6 months (95% CI: .02-.50) faster

230 In late perimenopause, INSTI+ had faster increases in WC (0.37 cm per 6 months

231 tion that mutant viruses carrying NNRTI plus INSTI resistance mutations had reduced amounts of virion

232 We assessed pre/post-INSTI weight changes from AIDS Clinical Trials Group par

233 Bictegravir is a novel, potent INSTI with a high in-vitro barrier to resistance and low

234 nce to antiretrovirals, including the potent INSTIs, in the absence of drug-target gene mutations.

235 cant improvement in survival between the pre-INSTI and INSTI recipients with HIV (adjusted hazard rat

236 cipients had higher mortality during the pre-INSTI era, but survival was comparable between groups du

237 y less likely than White patients to receive INSTI-containing ART in earlier time periods but not aft

238 A5095, A5142, and A5202 and did not receive INSTIs.

239 s A5095, A5142 and A5202 and did not receive INSTIs.

240 orized according to their first ART regimen (INSTI vs other ART) and were followed from ART start unt

241 strand transfer inhibitor (INSTI)-resistant (INSTI-R) virus is estimated at 0.1%.

242 intain ART success, particularly with rising INSTI use in all lines of therapy and 2-drug and long-ac

243 ing, all patients are diagnosed with INSTI-S/INSTI-R virus prior to ART initiation and start DTG- or

244 15% of African origin), 1837 (34.3%) started INSTI-based ART, and 3525 (65.7%) started other ART.

245 ith human immunodeficiency virus who started INSTI-based ART and those on other ART.

246 differences between individuals who started INSTIs and those who started other ART were -0.17% (95%

247 differs among treatment-naive PLWH starting INSTI-based regimens compared to other ART regimens.

248 Persons starting INSTIs vs. NNRTIs had incident DM risk (HR=1.17 [0.92-1.

249 uppression rates are 90% (INSTI-susceptible [INSTI-S] virus) and 35% (INSTI-R virus).

250 d to INSTI [INSTI+]; 712 who did not switch [INSTI-]) and 887 women without HIV (WWOH) from the Women

251 The INSTI-DM association was attenuated (HR=1.03 [0.71-1.49]

252 6-12 months before and 6-18 months after the INSTI switch/add in SWAD participants, with comparable m

253 iency virus (SIV) and HIV have clarified the INSTI binding modes within the intasome active sites and

254 val was comparable between groups during the INSTI era.

255 Among non-obese women, those in the INSTI versus non-INSTI group had a greater increase in N

256 ions underpins a fundamental weakness of the INSTI pharmacophore that is exploited by the virus to en

257 Using the INSTI Multiplex downward-flow immunoassay, we tested 200

258 Despite the INSTIs' proadipogenic and prolipogenic effects, these dr

259 These INSTIs induced adipogenesis, lipogenesis, oxidative stre

260 Compared to INSTI-, in late perimenopause, INSTI+ had 0.26 cm per 6

261 48 weeks following switch from efavirenz- to INSTI-based regimens among patients who had been virolog

262 ght gain following switch from efavirenz- to INSTI-based regimens.

263 ong patients who switched from efavirenz- to INSTI-based therapy, CYP2B6 genotype was associated with

264 ich harbored emerging resistance mutation to INSTI).

265 In WLHIV, a switch to INSTI was associated with significant increases in body

266 In WLHIV, a switch to INSTI was associated with significant increases in body

267 virally-suppressed WWH (419 who switched to INSTI [INSTI+]; 712 who did not switch [INSTI-]) and 887

268 in follow-up from 1997-2017 and switched to INSTI-based antiretroviral regimens were included.

269 is cohort study, infants exposed in utero to INSTI-based ART regimens had mean neurodevelopmental sco

270 d December 31, 2023, and exposed in utero to INSTI-based, PI-based, or NNRTI-based combination ART re

271 onths after baseline, and had no exposure to INSTIs before baseline.

272 S, and Q148H/K/R, which confer resistance to INSTIs.

273 and how the virus can develop resistance to INSTIs.

274 ether similar gains are seen after switch to INSTIs among virologically suppressed persons is less cl

275 ly weight gain increased following switch to INSTIs, particularly for women, blacks, and persons aged

276 ence change before and after first switch to INSTIs.

277 The 972 participants who switched to INSTIs were 81% male and 50% nonwhite with a median age

278 Compared to men, women switching to INSTIs experienced greater hip and thigh circumference g

279 to reduce the susceptibility of the virus to INSTIs.

280 Prevalence of transmitted INSTI-R virus did not affect the favored strategy.

281 itory quotients were determined using trough INSTI plasma concentrations.

282 ll effector functions in the presence of two INSTIs, dolutegravir and elvitegravir, which may contrib

283 Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a 10 day monotherapy st

284 ophylaxis, assessing virus suppression under INSTI-based regimens in prevention-relevant biologic com

285 inatally acquired HIV and on PI-based versus INSTI-based ART.

286 D/C/F/TAF, 0.63% [95% CI, -.44% to 1.70%] vs INSTI + TAF/FTC, -0.24% [95% CI, -1.35% to .87%]; P = .2

287 uring premenopause, WWH had increases in WC (INSTI+: 0.01 cm per 6 months [95% confidence interval {C

288 % [95% CI, -7% to -3%]) from 2009-2014, when INSTIs were approved as initial therapy but were not yet

289 .37 cm per 6 months [95% CI: .15-.60]) while INSTI- had smaller increases (0.14 cm per 6 months [95%

290 , peaking at 43 months then declining, while INSTI- had smaller increases (0.14 cm per 6 months [95%

291 in rural KwaZulu-Natal, prior to widespread INSTI usage, we enroled 18,025 individuals to characteri

292 With INSTI-based first-line regimens in the United States, ba

293 weeks undergo IR testing; if diagnosed with INSTI-R virus, they change to ritonavir-boosted darunavi

294 IR testing, all patients are diagnosed with INSTI-S/INSTI-R virus prior to ART initiation and start

295 All three patients with INSTI resistance mutations were highly resistant to dolu

296 30 June 2018, 22 762 (54%) were treated with INSTI-based regimens.

297 However, whether weight gain associated with INSTIs and tenofovir alafenamide confers a higher risk o

298 Initiating first cART regimens with INSTIs or PIs vs NNRTIs may confer greater risk of DM, l

299 Initiating first cART regimens with INSTIs or PIs vs. NNRTIs may confer greater risk of DM,

300 on mortality in people with HIV treated with INSTIs in routine care.